Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
By G. Sledge, D. Neuberg, P. Bernardo, J. Ingle, S. Martino, E. Rowinsky, W. Wood. Journal of Clinical Oncology, 2003
682 citations recorded by the source corpus.
Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/ef1c0d9dc5a2190d3032c9e904e2f5262fec291c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- N. Robert
- S. Phan
- E. Perez
- O. Lipatov
- S. Chan
- J. Glaspy
- V. Diéras
- Xian Zhou
Citations in the corpus
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. (2011, methodology): “A prior trial using a cross-over design showed PFS improvements but no OS difference.(18) As expected for a first-line MBC population, most patients had extensive exposure to subsequent lines of systemic therapy.”